ZURA stock forecast, quote, news & analysis
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need... Show more
Zura Bio Limited (ZURA) Stock Analysis: Enrollment Milestones Set Stage for Pivotal Phase 2 Data Readouts
Key Takeaways
- Zura Bio (ZURA) shares have traded in a volatile range between approximately $3.40 and $5.90 over the last quarter, reflecting the high-risk, catalyst-driven nature of clinical-stage biotechnology investing.
- The company exceeded enrollment targets in both Phase 2 trials of its lead candidate tibulizumab — TibuSHIELD in hidradenitis suppurativa and TibuSURE in systemic sclerosis — reinforcing investigator and patient demand.
- Analyst sentiment remains broadly constructive, with a consensus "Strong Buy" rating and an average 12-month price target of approximately $15.67, well above recent trading levels.
- Zura held $225.6 million in cash and equivalents as of March 31, 2026, providing a runway through at least the end of 2028 and reducing near-term dilution risk.
- Topline Phase 2 data from TibuSHIELD are expected in the fourth quarter of 2026, representing a potential binary catalyst for the stock.
Current Market Snapshot
Zura Bio Limited has experienced notable price swings in recent months but has shown relative stabilization in the last 30 days. After a steep decline from roughly $5.00 in early May to a low of $3.40 in early June — driven by broader biotech sector pressure and a Q1 2026 earnings miss — the stock staged a sharp recovery following the June 29 announcement that both Phase 2 tibulizumab trials had exceeded enrollment targets. Shares climbed as high as $5.90 on June 30 before settling into a trading range between roughly $5.00 and $5.70 through July. As of late July 2026, ZURA traded near $5.38, reflecting a modest gain of approximately 1–2% over the trailing 30-day period. The stock's 52-week range spans from $1.35 to $7.44, underscoring the wide valuation swings common among pre-revenue biotech companies approaching key clinical readouts.
Zura Bio Limited (ZURA) Business Overview and Competitive Position
Zura Bio is a clinical-stage, multi-asset immunology company focused on developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with significant unmet medical need. Headquartered in Henderson, Nevada, and founded in 2022, the company's pipeline is built around three product candidates in-licensed from leading pharmaceutical partners.
The lead asset, tibulizumab (ZB-106), is a potential first-in-class bispecific antibody that simultaneously targets interleukin-17A (IL-17A) and B-cell activating factor (BAFF) — two pathways central to inflammation and fibrosis in autoimmune disease. Tibulizumab is currently being evaluated in two global Phase 2 studies: TibuSHIELD in hidradenitis suppurativa (HS) and TibuSURE in systemic sclerosis (SSc). Both indications represent markets with limited effective treatment options and multi-billion-dollar commercial potential. The company's broader pipeline includes crebankitug (ZB-168), an anti-IL-7R antibody, and torudokimab (ZB-880), an anti-IL-33 antibody, both of which have completed Phase 1/1b studies.
Recent Developments Driving ZURA
The most significant catalyst in recent weeks was the June 29, 2026 announcement that Zura had completed enrollment in the Phase 2 TibuSHIELD trial with 247 participants — well above the 225-patient target — and that the TibuSURE trial had already surpassed its 80-participant enrollment goal. The oversubscription in both studies signaled strong investigator confidence and substantial unmet patient need. Zura also disclosed plans to initiate a Phase 2 study in a third immune-mediated indication by year-end 2026, expanding tibulizumab's clinical footprint.
Analyst activity has been a mixed but net-positive influence. On July 8, William Blair initiated coverage with an Outperform rating, projecting peak global sales of $2.3 billion for tibulizumab in HS and $1.6 billion in SSc, with a combined net present value of over $12 per share. Guggenheim, Wedbush, Oppenheimer, and Piper Sandler have each maintained Buy or Outperform ratings with price targets ranging from $15 to $26. Conversely, Wall Street Zen downgraded the stock from "Sell" to "Strong Sell" on July 12, and Weiss Ratings reiterated a bearish call — reflecting the inherent divergence of opinion around binary clinical-stage assets.
On the financial front, Zura ended Q1 2026 with $225.6 million in cash following a $144 million public offering completed in February 2026. Management has guided that existing cash is sufficient to fund operations through at least the end of 2028, covering both anticipated Phase 2 readouts and the planned third-indication trial.
Trending AI Robots
For traders and investors seeking automated, data-driven approaches to navigate volatile markets, Tickeron's Trending AI Robots page offers a curated view of top-performing AI trading bots. Tickeron hosts hundreds of AI-powered trading bots that actively trade thousands of tickers across equities, ETFs, and cryptocurrencies, but only the most relevant and consistently strong performers are featured in the Trending section. These bots employ diverse strategies — ranging from swing trading and trend following to mean-reversion and breakout models — and operate across different timeframes and performance metrics. The curated list helps users identify AI-driven strategies with demonstrated real-time results, providing a starting point for exploring systematic trading approaches.
2026 Outlook and What Investors Should Watch
The remainder of 2026 is poised to be a defining period for Zura Bio. The single most important event on the horizon is the anticipated release of topline data from the Phase 2 TibuSHIELD trial in hidradenitis suppurativa, expected in the fourth quarter of 2026. This readout will provide the first randomized, placebo-controlled efficacy data for tibulizumab and will likely serve as a binary inflection point for the stock.
Investors should also monitor the announcement of the third indication for tibulizumab, expected before year-end, which could broaden the drug's addressable market and reinforce the dual-pathway thesis. The Phase 2 TibuSURE readout in systemic sclerosis, now expected in the first half of 2027, represents a secondary but important catalyst. Macroeconomic factors — including Federal Reserve policy, sector rotation within healthcare, and risk appetite for pre-revenue biotech — will continue to influence sentiment. Additionally, competitive developments in the immunology space, particularly around IL-17 and BAFF-targeted therapies, regulatory updates, and any changes in institutional ownership, warrant close attention.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ZURA in +5.93% Uptrend, rising for three consecutive days on July 28, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ZURA advanced for three days, in of 174 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
ZURA moved above its 50-day moving average on June 25, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ZURA crossed bullishly above the 50-day moving average on July 01, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 191 cases where ZURA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for ZURA moved out of overbought territory on July 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 60 cases where ZURA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on July 31, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ZURA as a result. In of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ZURA turned negative on July 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 59 similar instances when the indicator turned negative. In of the 59 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZURA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ZURA broke above its upper Bollinger Band on July 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ZURA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.378) is normal, around the industry mean (19.620). P/E Ratio (7.956) is within average values for comparable stocks, (38.277). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.532). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (420.906).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZURA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology